Author
The Biden Administration could take a number of legal measures to ensure the timely entrance of a generic competitor to Xtandi.
The proposal introduces precedents that will be used to justify further narrowing of TRIPS flexibilities.
This digital symposium for the Petrie-Flom Center’s Bill of Health blog explores the role psychedelics may play in America’s future.
Psychedelics may fill the growing need for innovative psychiatric drugs. Some cities, dissatisfied with the U.S. war on drugs, are decriminalizing them.
By James Love This is a story about U.S. patent number 6,958,335, and how it took more than 18 years for Novartis to acknowledge National Institutes of Health (NIH) funding in a key patent for…
There are several issues with the proposed U.S.-Mexico-Canada trade agreement on drug pricing, including that it both will lock in bad features of current laws, and is inconsistent with U.S. law.
By James Love The United States, like other countries, uses the grant of legal monopolies as the incentive to reward successful R&D investments. The legal mechanisms are varied, and include most importantly patents on medical…
By James Love The Senate HELP committee held a hearing on June 12 on “The Cost of Prescription Drugs: Examining the President’s Blueprint ‘American Patients First’ to Lower Drug Prices” where Secretary Alex Azar…
By James Love On November 17, 2017, Genentech, a subsidiary of the giant Swiss drug company Roche, together with City of Hope, a charity, filed a complaint in a U.S. District Court, seeking an injunction…
By James Love Recently I have become interested in the frequency of a “certificate of correction” on a granted patent, after two efforts to establish federal rights in patents granted. The first case involved the…
